腫瘤的免疫治療日益受到社會關注與重視，隨著新型免疫治療，特別是針對免疫檢查點靶向藥物的蓬勃發(fā)展，已成為當下腫瘤治療領域最具前景的發(fā)展方向之一。轉化醫(yī)學作為腫瘤基礎研究和臨床免疫治療之間的橋梁，通過對特異性生物標志物的發(fā)掘，來優(yōu)化臨床研究設計，并探索最佳的藥物聯(lián)合治療模式。其中，動物實驗往往是轉化醫(yī)學研究的第一步。

本次研討會是由和鉑醫(yī)藥主辦，并邀請Jackson laboratory和上海南方模式生物專家針對腫瘤免疫治療中的人源化小鼠模型開發(fā)及應用進行交流。

時間：2019年10月31日13:00-15:00

地點：上海實驗動物中心一號樓一號報告廳

演講嘉賓

James Keck

Senior Director, In Vivo Pharmacology & Clinical Lab Services, Jackson Laboratory

In Jackson Laboratory, Dr.Keck has overall responsibility for the innovativearray of new scientific tools and services based on proprietary capabilities inhumanized mice and genomics to facilitate discovery and development of new waysto treat human disease. The preclinical efficacy studies using PDX and other models hu- NSGTM miceis under his direction. In addition, Dr.Keck was also responsible for the initiation of business development activities with corporations for the purpose of developing cutting edge platform based programs.

Topic：Theuse of humanized mice for immuno-oncology research and drug development.

Ruilin Sun

Vice president, Shanghai Model Organisms Center, Inc

Topic: The use of genetically modified mice for immuno-oncology research and durg development.?